Previous Close | N/A |
YTD Return | N/A |
Expense Ratio (net) | N/A |
Category | N/A |
Last Cap Gain | N/A |
Morningstar Rating | N/A |
Morningstar Risk Rating | N/A |
Sustainability Rating | N/A |
Net Assets | N/A |
Beta (3Y Monthly) | N/A |
Yield | N/A |
5y Average Return | N/A |
Holdings Turnover | N/A |
Last Dividend | N/A |
Average for Category | N/A |
Inception Date | N/A |
WATERTOWN, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- athenahealth, Inc., a leading provider of network-enabled healthcare IT services for ambulatory and enterprise customers nationwide, announced today that it has been recognized as a Leader in Frost & Sullivan’s Frost Radar in the US Healthcare Data Analytics Market. Of the more than 150 companies offering both modular and plug-in analytics solutions in the US healthcare marketplace, athenahealth was one of only six companies selected as a Leader for scoring high on both the Growth and Innovation indices in the Frost Radar report. According to the Frost Radar report, the US healthcare data analytics market is valued at $7.9B in 2019 and expected to grow at a compound annual growth rate of 15.75% from 2019 to 2024 to reach $16.52B.
Two key healthcare customer gatherings recently drew more than 1,500 leaders, system users and organizational decision makers to connect, engage and learn about athenahealth’s vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. The events were the annual Centricity Healthcare User Group, where athenahealth was a platinum sponsor, keynote speaker and led over 15 breakout sessions; and the 2019 Success Summit hosted by athenahealth, leading provider of network-enabled services for healthcare provider organizations nationwide. As the largest independent user-led event within the healthcare industry for customers of CentricityTM Practice Solution and CentricityTM Electronic Medical Record (EMR), attendees heard from athenahealth’s Chief Customer Officer Bret Connor who announced substantial new investments in support for those customers, including the rollout of dedicated Customer Success Managers (CSMs).
WATERTOWN, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- athenahealth, Inc., a leading provider of network-enabled services for ambulatory and hospital customers nationwide, announced today that Luis Borgen has joined the company as Chief Financial Officer (CFO). Luis most recently served as CFO for Vistaprint, a global e-commerce brand that empowers small businesses to market themselves with physical and digital marketing products. In his new role, Borgen will lead athenahealth’s finance organization to help propel the company’s strategic goals.
The healthcare space might have seen a sluggish year so far. But its valuation and near-term prospects make it a good space for investments right now.
Twenty years ago, Paul J. Glazer launched his own merger arbitrage hedge fund, which he called Glazer Capital. The fund, which has $1.3 billion in AUM (as of June 6th, 2017) is headquartered in New York City, and it was registered with the US Securities and Exchange Commission as an Investment Adviser in 2006. Paul […]
Athenahealth (ATHN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
athenahealth (ATHN) gains from a broad product portfolio. However, it faces stiff competition in the MedTech space.
Cerner's (CERN) coveted Millennium platform has seen rising demand in recent times.
The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.
NEW YORK, Jan. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.
Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.
ResMed (RMD) progresses with efforts to boost Respiratory Care suite.
QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.
Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.
ResMed (RMD) expects to boost the Respiratory Care suite with the recently-completed Propeller Health buyout.
NEW YORK, Jan. 07, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
Cardiovascular Systems (CSII) continues to expand its portfolio to widen the company's reach. However, Cardiovascular Systems operating in a highly competitive environment is a concern.
Neogen (NEOG) continues to adopt initiatives to boost the genomics business.